SCHEMBL6209355

SCHEMBL6209355

O=C(O)C1=CC=CNC=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5791560 0.82
SCHEMBL28296127 0.79 NPSR1 (0.34)
SCHEMBL5064035 0.67
SCHEMBL22747796 0.66 SLC22A6 (0.30)
SCHEMBL28333042 0.65
SCHEMBL23833210 0.62
SCHEMBL31185706 0.62
SCHEMBL7853628 0.62
SCHEMBL28105511 0.62
SCHEMBL1238252 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569935-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-07 EP claimed
WO-2004052891-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-06-24 WO claimed
CN-112513049-B Heterocyclic compounds and their use in the prevention or treatment of bacterial infections 拜欧蒂姆公司 2023-11-28 CN disclosed
EP-4243816-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2023-09-20 EP disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
WO-2022104206-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2022-05-19 WO disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed
CN-112513049-A Heterocyclic compounds and their use in the prevention or treatment of bacterial infections 拜欧蒂姆公司 2021-03-16 CN disclosed
EP-3558287-A2 N-ACETYLDIAMINOBUTYRIC ACID-CONTAINING COMPOSITION Bitop AG (DE) 2019-10-30 EP disclosed
CN-109843892-A Dislike diazepine ketone derivatives and its purposes in treatment hepatitis B infection 诺维拉治疗公司 2019-06-04 CN disclosed
CN-109641896-A DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS 诺维拉治疗公司 2019-04-16 CN disclosed
EP-1569935-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS Aventis Pharma S.A. (FR) 2005-09-07 EP disclosed
WO-2004052891-A1 HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-06-24 WO disclosed
EP-1366066-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-03 EP disclosed
WO-2002072621-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-19 WO disclosed